Advanced Ovarian Cancer — Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin
Citation(s)
Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.